FDA-Approved Janus Kinase-Signal Transducer and Activator of Transcription (JAK-STAT) Inhibitors for Managing Rheumatoid Arthritis: A Narrative Review of the Literature.

Autor:	Potlabathini T; Internal Medicine, Malla Reddy Institute of Medical Sciences, Hyderabad, IND., Pothacamuri MA; Internal Medicine, Kasturba Medical College, Mangalore, Mangalore, IND., Bandi VV; Medicine and Surgery, Guntur Medical College, Guntur, IND., Anjum M; Medicine, King Edward Medical University, Lahore, PAK., Shah P; Internal Medicine, Dali University, Dali, CHN., Molina M; Internal Medicine, International Medical Graduates (IMG) Helping Hands, Newark, USA., Dutta N; General Medicine, North Bengal Medical College and Hospital, Siliguri, IND., Adzhymuratov O; Medicine and Surgery, Dnipro State Medical University, Dnipro, UKR., Mathew M; Internal Medicine, Pennsylvania Hospital, Philadelphia, USA., Sadu V; Medicine and Surgery, Kamineni Academy of Medical Sciences and Research Centre, Hyderabad, IND., Zahid SA; Medicine and Surgery, Jinnah Sindh Medical University, Karachi, PAK., Lingamgunta H; Medicine, All Saints University School of Medicine Dominica, Chicago, USA., Sahotra M; Internal Medicine, International Medical Graduates (IMG) Helping Hands, San Pablo, USA., Nasiri SMZJ; Anesthesia and Critical Care, Ibn-e-Siena Hospital & Research Institute, Multan, PAK., Daguipa CDM; Medicine, Far Eastern University - Dr. Nicanor Reyes Medical Foundation, Quezon City, PHL.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2024 May 09; Vol. 16 (5), pp. e59978. Date of Electronic Publication: 2024 May 09 (Print Publication: 2024).
DOI:	10.7759/cureus.59978
Abstrakt:	Rheumatoid arthritis (RA) is a complex autoimmune disease causing chronic joint inflammation and, in more serious cases, organ involvement. RA typically affects people between the ages of 35 and 60; however, it can also afflict children younger than the age of 16 years and can also demonstrate a pattern of remission later in the disease course. Non-steroidal anti-inflammatory drugs, glucocorticoids, exercise, and patient education are all used in the management of RA, which is divided into symptomatic management and disease-modifying management (disease-modifying antirheumatic drugs) to reduce pain and inflammation, thereby preserving joint function. Janus kinase inhibitors (JAKis) have led to a substantial improvement in the management of RA. By specifically targeting the JAK-signal transducer and activator of transcription pathway, which is essential for immunological modulation, these inhibitors also demonstrate promise in treating various autoimmune illnesses, including inflammatory bowel diseases, giant cell arteritis, ankylosing spondylitis, and psoriatic arthritis. Tofacitinib, baricitinib, upadacitinib, peficitinib, delgocitinib, and filgotinib are examples of FDA-approved JAKis that have distinct properties and indications for treating a range of autoimmune illnesses. JAKis demonstrate a promising treatment approach for managing RA and other autoimmune diseases while enhancing patient outcomes and quality of life. However, due to major safety concerns and the need for long-term success, meticulous patient monitoring is essential. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2024, Potlabathini et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu